Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
5
Active, not recruiting, industry sponsors, Kidney and urology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed218
5 trials
Showing 1 to 5, recently updated first.
- A Pharmacokinetic Study of Budesonide Delayed Release Tablet D23A (D23) in Healthy Chinese Participants Under Fasting ConditionsActive, not recruiting
Triastek, lnc.Industry
NCT07925216 · 18 participants (planned) · Start Nov 3, 2026 · Primary completion Jan 2027
Drug: Budesonide delayed release tablet 4mg; Budesonide Delayed Release Capsules and 1 more · For: IgA Nephropathy (IgAN)
Sites: Suzhou, China
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruiting
Alpine Immune Sciences, Inc.Industry
NCT05732402 · 72 participants · Start Mar 15, 2023 · Primary completion Mar 2, 2028
Drug: Povetacicept · For: Lupus Nephritis; Immunoglobulin A Nephropathy; Membranous Nephropathy and 1 more
Sites: Phoenix, Arizona; Tucson, Arizona; Valencia, California · 30 sites in all
- A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal ImpairmentActive, not recruiting
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.Industry
NCT07445906 · 24 participants (planned) · Start Mar 15, 2026 · Primary completion Dec 1, 2026
Drug: RG002C0106 · For: Renal Impairments; IgA Nephropathy (IgAN)
Sites: Beijing, China
- A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)Active, not recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT06799520 · 30 participants (planned) · Start Mar 17, 2025 · Primary completion Oct 19, 2026
Drug: VIS171 · For: Systemic Lupus Erythematosus (SLE); Alopecia Areata (AA); Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Sites: Sofia, Bulgaria; Chisinau, Moldova; Bucharest, Romania · 6 sites in all
- A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)Active, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05092347 · 43 participants · Start Aug 2, 2022 · Primary completion Nov 22, 2027
Drug: Vonsetamig · For: Chronic Kidney Disease (CKD)
Sites: Los Angeles, California; Orange, California; San Francisco, California · 10 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.